In addition, we identified and functionally validated alternative driver genetic alterations restricted to the HER2-negative component of HER2 heterogeneous breast cancers, including BRF2 and DSN1 amplification, and a HER2 somatic mutation. Here, BRF2 is linked to breast carcinoma.